Wilco

AI voice and messaging agents for healthcare clinics to manage patient follow-up.

Website: https://www.getwilco.ai/

Cover Block

Open sources

Field Value
Name Wilco
Tagline AI voice and messaging agents for healthcare clinics to manage patient follow-up. [getwilco.ai, retrieved 2026]
Headquarters Madrid, Spain [EU-Startups, Nov 2026]
Founded 2020 [Tracxn, 2026]
Stage Seed [EU-Startups, Nov 2026]
Business Model SaaS
Industry Healthtech
Technology AI / Machine Learning
Geography Western Europe
Growth Profile Venture Scale
Funding Label Seed
Total Disclosed Funding $2,680,000 [EU-Startups, Nov 2026]

Links

Open sources

What an Investor Needs First

PUBLIC Wilco sells AI voice and messaging agents for healthcare clinics, a timely wedge because patient follow-up remains administratively heavy and the company has just announced fresh seed financing to expand across Europe [getwilco.ai, retrieved 2026] [EU-Startups, Nov 2026]. Public reporting places the company in Madrid, founded in 2020, with a seed round of €2.5 million, approximately $2.68 million, led by Samaipata, which gives investors an early but concrete financing marker around a workflow that clinics already pay staff to manage [EU-Startups, Nov 2026] [Capital-Riesgo.es, Nov 2026].

The product claim is straightforward: Wilco says its platform follows patients from first inquiry through treatment-plan signature and subsequent visits, using AI agents across voice and messaging rather than a single chat surface [getwilco.ai, retrieved 2026]. The differentiation, based on public materials, appears to be vertical specificity by clinic workflow and specialty coverage, including dental, medical aesthetics, veterinary, physiotherapy, ophthalmology, and dermatology, with use cases ranging from missed calls and unconfirmed bookings to unsigned treatment plans and overdue reviews [getwilco.ai, retrieved 2026] [getwilco.ai/clinics, retrieved 2026].

The public record on the founding team is thin. No founder names were confirmed in the supplied source set, so the investable argument in the public half rests more on category timing and early market positioning than on a clearly documented operator pedigree [EU-Startups, Nov 2026] [Tracxn, 2026].

On traction, the strongest public datapoint is company-reported scale: Wilco says it has handled more than 1.5 million patient calls, but that figure remains company-only and should be treated as directional until independently corroborated [getwilco.ai, retrieved 2026]. Independent and semi-independent coverage is at least consistent on the core workflow, describing Wilco as using AI agents to help clinic groups with patient follow-up and treatment-plan acceptance [Startups Españolas, Nov 2026] [healthtechrounds.substack.com, 2026].

The business model is presented as SaaS, and the newly surfaced hiring signal, a deployment strategist role focused on customer implementation and expansion, fits an enterprise or multi-site clinic motion where onboarding and retention matter as much as initial sale [freehire.me, retrieved 2026]. Over the next 12 to 18 months, the main items to watch are whether Wilco can convert workflow breadth into repeatable deployments across specialties, show independent proof of customer adoption beyond company materials, and translate seed capital into evidence that these AI agents improve attendance, plan conversion, or return visits at clinic-group level [EU-Startups, Nov 2026] [getwilco.ai, retrieved 2026].

Claim stands unchecked -- This section relies materially on company website claims for product scope and traction, with public funding details corroborated by EU-Startups and Capital-Riesgo.es.

Taxonomy Snapshot

Axis Value
Stage Seed
Business Model SaaS
Industry / Vertical Healthtech
Technology Type AI / Machine Learning
Geography Western Europe
Growth Profile Venture Scale
Funding Disclosed seed financing of approximately $2.68M, reported as €2.5M led by Samaipata

Inside the Company

PUBLIC

Wilco presents as a Madrid-based healthtech software company focused on one narrow workflow inside clinics: patient follow-up after an initial inquiry and before, between, and after visits [getwilco.ai, retrieved 2026]. The public record is still thin, but the core outline is clear enough. The company says it was founded in 2020, is headquartered in Madrid, and sells an AI patient follow-up platform built around voice and messaging agents for healthcare clinics [Tracxn, 2026] [getwilco.ai, retrieved 2026].

The milestone that is most clearly corroborated in public sources is the November 2026 seed financing. Wilco announced a €2.5 million seed round led by Samaipata, with ABAC Nest Ventures also named among investors, according to company-backed coverage and database profiles [EU-Startups, Nov 2026] [Tracxn, 2026]. Around the same period, the company described its product as helping clinics move patients from first enquiry through treatment-plan signature and follow-up visits, with specialty pages aimed at dental, medical aesthetics, veterinary, physiotherapy, ophthalmology, and dermatology practices [getwilco.ai, retrieved 2026] [getwilco.ai, retrieved 2026].

A small hiring signal suggests the business is building customer-facing implementation capacity rather than operating as a pure self-serve tool. A 2026 job post for a Deployment Strategist, Customer Implementation & Expansion points to hands-on onboarding and account expansion as part of the operating model [freehire.me, retrieved 2026]. That does not establish scale on its own, but it fits the profile of a clinic software vendor selling into workflows that usually require integration, change management, or both [freehire.me, retrieved 2026].

Partially corroborated -- Company HQ, product scope, and workflow claims are supported primarily by the company website, with partial corroboration on founding year and funding from Tracxn and EU-Startups.

Under the Hood

MIXED

What Wilco is selling, at least from the public record, is fairly clear even if the underlying technical detail is still thin. The company describes itself as an AI patient follow-up platform for healthcare clinics, built around voice and messaging agents that stay with a patient from first inquiry through treatment-plan signature and the next visit [getwilco.ai, retrieved 2026]. Separate coverage in Spanish startup press is directionally consistent on the use case, describing AI agents for patient follow-up and treatment-plan acceptance at clinic groups [Startups Españolas, Nov 2026] [healthtechrounds.substack.com, 2026].

The functional scope on the website is broader than a simple reminder tool. Wilco says the system handles missed calls, unanswered inquiries, unconfirmed bookings, changes and cancellations, no-shows, unsigned plans, cost concerns, treatment questions, overdue reviews, vaccines and deworming, unfinished treatment, and patient referrals [getwilco.ai, retrieved 2026]. It also lists target specialties that include dental, medical aesthetics, veterinary, physiotherapy, ophthalmology, and dermatology clinics [getwilco.ai/clinics, retrieved 2026]. That suggests a workflow product aimed at reducing patient drop-off across several high-frequency administrative and conversion points, though the public material does not establish how much of the workflow is fully automated versus staff-supervised.

The harder question is technical differentiation, and here the evidence is narrower. Wilco's public materials support the presence of AI voice and messaging agents, but they do not publicly document model providers, integrations, deployment architecture, or measurable accuracy by workflow type [getwilco.ai, retrieved 2026]. One open role, Deployment Strategist for Customer Implementation and Expansion, points to an implementation-heavy motion and implies that onboarding and clinic expansion may be operationally important to product success (inferred from job postings) [freehire.me, retrieved 2026]. The company also states that it has handled more than 1.5 million patient calls, which, if accurate, would indicate meaningful live usage, but that figure appears company-supplied and is not independently corroborated in the sources reviewed [getwilco.ai, retrieved 2026].

Claim stands unchecked -- This section relies primarily on company website claims, with partial corroboration from startup press and one public job posting.

Market Research

PUBLIC

Healthcare clinics have a simple economic problem that AI is increasingly being asked to solve: too many patient conversations happen late, inconsistently, or not at all, and revenue can slip well before a clinician delivers care [getwilco.ai, retrieved 2026] [TechCrunch, Jan 2025].

The available public record does not provide a direct third-party TAM, SAM, or SOM for Wilco's specific wedge, which is AI voice and messaging agents for patient follow-up in clinics [getwilco.ai, retrieved 2026]. The closest cited market evidence in the source set is adjacent rather than exact. TechCrunch's January 2025 coverage of Hippocratic AI points to investor appetite for patient-facing AI agents in healthcare, which supports the view that automated clinical communication is becoming a fundable application layer rather than a fringe workflow tool [TechCrunch, Jan 2025]. That said, the cited sources here do not quantify the addressable market for follow-up automation across European outpatient clinics, so any numerical sizing would be speculative.

Demand signals are clearer than market sizing. Wilco's public positioning centers on missed calls, unconfirmed bookings, no-shows, unsigned treatment plans, overdue reviews, and similar points of patient drop-off [getwilco.ai, retrieved 2026]. Those are operational failures with visible economic consequences for clinic operators, particularly in specialties where conversion from inquiry to booked treatment matters as much as pure visit volume, such as dental, medical aesthetics, physiotherapy, ophthalmology, dermatology, and veterinary care [getwilco.ai/clinics, retrieved 2026]. Independent write-ups describe Wilco's product in similar terms, emphasizing AI agents used by clinic groups to improve consultations reached and treatment-plan acceptance, which suggests the company is aiming at revenue-cycle-adjacent workflows rather than purely administrative chat support [Startups Españolas, Nov 2026] [healthtechrounds.substack.com, 2026].

The substitute set is broad, which matters for adoption. Clinics can try to solve the same problem with front-desk staff, call centers, generic CRM and messaging software, appointment-reminder tools, or broader patient engagement platforms, even if those products were not named in the source base [getwilco.ai, retrieved 2026]. The adjacent market is therefore larger than "healthcare AI agents" alone. It also includes practice management, patient relationship management, scheduling, and treatment conversion software. That broadens the opportunity, but it also means Wilco is likely selling into a budget line that already has incumbents and manual workarounds.

Macro and regulatory forces cut both ways. On the positive side, the November 2026 funding coverage frames Wilco's expansion thesis around scaling across Europe, which implies that investors see room for cross-border demand in clinic communication workflows [EU-Startups, Nov 2026] [Capital-Riesgo.es, Nov 2026]. On the constraint side, healthcare communication products operate in a category where data handling, consent, workflow reliability, and local compliance expectations can slow deployment, even when the user value proposition is straightforward. The cited sources do not spell out Wilco's regulatory posture in detail, so the prudent reading is that execution will depend not just on model quality but on integration and compliance credibility.

Market claim Relevance to Wilco Evidence
Patient-facing AI agents are attracting large-scale venture funding in healthcare Supports category formation around automated healthcare communication Hippocratic AI raised $141 million in January 2025 [TechCrunch, Jan 2025]
Clinic groups are being targeted for AI-led patient follow-up and treatment conversion Supports buyer and workflow relevance in outpatient settings Wilco's funding coverage describes AI agents for clinic groups and treatment-plan acceptance [Startups Españolas, Nov 2026] [healthtechrounds.substack.com, 2026]
Wilco announced a €2.5 million seed round to scale across Europe Suggests investors see regional expansion potential in this workflow category Seed round led by Samaipata [EU-Startups, Nov 2026] [Europa Press, Nov 2026]

The evidence here is enough to support a real category need, but not enough to claim a measured market size. The more defensible public conclusion is that Wilco sits at the intersection of patient engagement, clinic operations, and healthcare AI agents, a credible wedge if deployment friction stays manageable.

Partially corroborated -- Market interpretation relies on adjacent public reporting and company positioning, with partial corroboration from EU-Startups, Startups Españolas, Capital-Riesgo.es, Europa Press, and TechCrunch.

Competition and Substitutes

Competitive positioning

MIXED Wilco sits in the patient-engagement layer of healthcare software, closer to follow-up automation than to core clinical systems, and that places it against a wider field than the company’s own category language suggests [getwilco.ai, retrieved 2026] [Startups Españolas, Nov 2026].

The nearest competitive set is not fully disclosed in the source pack, so the map has to be drawn from adjacent public categories rather than a closed list of confirmed rivals. On one side are incumbents such as practice-management systems, CRM tools, and clinic communications software that already own appointment reminders, inbound messaging, or front-desk workflow in outpatient settings [TechCrunch, Jan 2025]. On the other side are newer AI agent vendors building patient-facing voice and messaging products, with Hippocratic AI the clearest named reference in the materials, although its public positioning is broader and more healthcare-system oriented than Wilco’s clinic follow-up focus [TechCrunch, Jan 2025]. A third bucket is substitution by manual operations, where clinics rely on reception staff, treatment coordinators, and outsourced call centers rather than software to recover missed inquiries, confirmations, and dormant patients [getwilco.ai, retrieved 2026].

Wilco’s edge, based on public evidence, appears to be vertical specificity rather than scale. The company describes workflows that are unusually tied to conversion and retention inside clinics, including missed calls, unsigned treatment plans, no-shows, overdue reviews, and specialty-specific use cases across dental, aesthetics, veterinary, physiotherapy, ophthalmology, and dermatology [getwilco.ai, retrieved 2026] [getwilco.ai/clinics, retrieved 2026]. If that product depth reflects real deployment logic rather than website packaging, the advantage would come from workflow tuning and message training data gathered around clinic follow-up behavior. That is useful, but still perishable. Larger communications vendors or better-capitalized AI agent platforms could reproduce much of the feature set if distribution into clinics proves attractive enough [TechCrunch, Jan 2025].

The company is most exposed where control of the customer relationship sits upstream of follow-up. Core systems vendors, appointment platforms, and established healthcare communications software often already control the scheduling record, patient contact permissions, and day-to-day staff workflow, which can make them the default place to add automation before a clinic buys a separate layer [TechCrunch, Jan 2025]. Hippocratic AI represents a different kind of pressure: not direct like-for-like competition in the source set, but a signal that patient-facing agents are drawing serious capital and could move downmarket into narrower clinic use cases over time [TechCrunch, Jan 2025]. Wilco’s single confirmed open role in deployment and expansion also hints that implementation capacity may matter as much as model quality in winning accounts, particularly for multi-site groups that need onboarding and workflow change management [freehire.me, retrieved 2026].

Over the next 18 months, the most plausible scenario is a sorting of the category by distribution and clinical workflow access rather than by model novelty alone. Wilco is well placed if outpatient clinics keep buying point solutions that directly improve attendance and treatment-plan conversion, and if specialty tailoring proves difficult for horizontal vendors to replicate quickly [EU-Startups, Nov 2026] [Healthtech Rounds #06, 2026]. Hippocratic AI is the clearest winner if larger, well-funded patient-agent platforms can extend from broad patient interaction into clinic-specific follow-up with credible integrations and compliance posture at scale [TechCrunch, Jan 2025]. The likeliest loser, if core systems absorb these features natively, is the standalone follow-up layer as a category rather than any one named startup. On today’s evidence, Wilco’s position is interesting but not yet insulated.

Partially corroborated -- Competitive framing relies on company materials for product scope, with partial corroboration from startup funding coverage and one independent market reference to patient-facing AI agents [getwilco.ai, retrieved 2026] [Startups Españolas, Nov 2026] [TechCrunch, Jan 2025].

Opportunity

Upside Case

PUBLIC The prize here is straightforward: if Wilco becomes the operating layer for patient follow-up across fragmented outpatient clinics in Europe, a narrow workflow product could compound into a category platform for revenue recovery, patient retention, and treatment conversion in specialties where missed calls and unclosed treatment plans carry direct economic cost [getwilco.ai, retrieved 2026] [EU-Startups, Nov 2026].

The headline opportunity is not that Wilco sells generic AI to healthcare. It is that it applies voice and messaging agents to one of the most repetitive and commercially material gaps inside clinics, the interval between first inquiry and completed treatment, where drop-off appears common enough for multiple publications to frame the product around reducing missed consultations and improving treatment-plan acceptance [getwilco.ai, retrieved 2026] [Startups Españolas, Nov 2026] [Healthtech Rounds #06, 2026]. That outcome is still early, but not purely aspirational: Wilco has already attracted a seed round led by Samaipata and described by several outlets as capital intended to scale across Europe, which suggests investors see the use case as broader than a single-country services business [EU-Startups, Nov 2026] [Capital-Riesgo.es, Nov 2026] [Dealroom News, 2026].

The upside paths are easiest to think about as a small set of concrete expansion motions. The table below keeps those paths grounded in the limited public evidence.

Scenario What happens Catalyst Why it's plausible
Multi-specialty clinic standard Wilco becomes the default patient follow-up system for independent clinics and clinic groups across dental, aesthetics, ophthalmology, dermatology, physiotherapy, and veterinary care Cross-specialty proof that one workflow engine can support several clinic types without heavy product fragmentation Wilco already markets into each of those specialties, which implies management believes the workflow is portable across outpatient categories [getwilco.ai/clinics, retrieved 2026]
Europe-wide consolidation layer Wilco expands from Spain into broader Western Europe as clinics look for software that recovers lost demand without adding front-desk headcount Seed capital earmarked for European expansion and a repeatable deployment motion EU-Startups reported a €2.5 million seed round to scale the AI patient follow-up platform across Europe, and an open deployment strategist role points to implementation capacity becoming a bottleneck worth hiring against [EU-Startups, Nov 2026] [freehire.me, retrieved 2026]
Patient-engagement system of record The product moves from reminders and reactivation into a broader patient communication layer tied to treatment-plan acceptance and return visits Higher model performance in voice and messaging agents for patient-facing healthcare tasks Wilco already frames its product from first inquiry through signed treatment and next visit, while broader investor attention to patient-facing AI agents suggests the market is maturing around this interface layer [getwilco.ai, retrieved 2026] [TechCrunch, Jan 2025]

What compounding could look like is less about a classic consumer network effect and more about workflow entrenchment. If Wilco consistently handles missed calls, booking confirmations, cancellations, no-shows, unsigned plans, treatment questions, overdue reviews, and referral prompts inside the same clinic relationship, each additional workflow should deepen dependence on the system and widen the switching cost tied to staff process, patient communication history, and specialty-specific scripting [getwilco.ai, retrieved 2026]. The strongest early hint is breadth: the company is not presenting a single reminder bot, but a stack of adjacent follow-up jobs that all sit close to revenue capture and utilization [getwilco.ai, retrieved 2026] [Healthtech Rounds #06, 2026]. If that breadth translates into measurable lift for clinics, expansion from one specialty or one location into a multi-site estate becomes a plausible land-and-expand motion.

The size of the win is hard to pin down from public evidence because no verified market-sizing data or revenue base is available here. Still, there is a credible marker for strategic value in the category: TechCrunch reported in January 2025 that Hippocratic AI, focused on patient-facing AI agents, raised $141 million, underscoring investor appetite for software that sits directly in patient communication rather than back-office automation alone [TechCrunch, Jan 2025]. If Wilco were to become a leading European patient-follow-up platform across fragmented outpatient care, the outcome could support a venture-scale business worth hundreds of millions of dollars in enterprise value (scenario, not a forecast), particularly if it proves that AI-led follow-up improves consultation attendance and treatment conversion at clinic-group level [TechCrunch, Jan 2025] [EU-Startups, Nov 2026]. The gap, and the reason this remains an upside case rather than a base case, is that public evidence has not yet established those operating metrics.

Partially corroborated -- Relies on one independently reported financing event and multiple company-led product claims, with partial corroboration from sector coverage and job-posting evidence [EU-Startups, Nov 2026] [Capital-Riesgo.es, Nov 2026] [getwilco.ai, retrieved 2026] [freehire.me, retrieved 2026].

Sources

Open sources

  1. [getwilco.ai, retrieved 2026] Wilco | AI patient follow-up for healthcare clinics | https://www.getwilco.ai/

  2. [EU-Startups, Nov 2026] Madrid-based Wilco secures €2.5 million to scale its AI patient follow-up platform across Europe | EU-Startups | https://www.eu-startups.com/2026/11/madrid-based-wilco-secures-e2-5-million-to-scale-its-ai-patient-follow-up-platform-across-europe

  3. [Capital-Riesgo.es, Nov 2026] Wilco closes €2.5 million funding round led by Samaipata to help healthcare clinics close more treatments with AI agents | https://capital-riesgo.es/en/articles/wilco-closes-2-5m-eur-funding-round-led-by-samaipata-to-help-healthcare-clinics-close-more-treatments-with-ai-agents/

  4. [Tracxn, 2026] Wilco - 2026 Company Profile, Funding & Competitors - Tracxn | https://tracxn.com/d/companies/wilco/__TacJGVIpX7gsnK2OOs-lkBtUO61b_g3B9xF0TeQmV30

  5. [freehire.me, retrieved 2026] Deployment Strategist, Customer Implementation & Expansion , Wilco | https://freehire.me/jobs/deployment-strategist-customer-implementation-expansion-wilco-qrapm75e

  6. [Startups Españolas, Nov 2026] Wilco cierra 2,5 M€ con Samaipata para IA en clínicas | https://startups-espanolas.es/wilco-cierra-25-millones-con-samaipata-para-sus-agentes-de-ia-en-clinicas/

  7. [healthtechrounds.substack.com, 2026] Healthtech Rounds #06: Isomorphic Labs raises US$ 5B in Series C | https://healthtechrounds.substack.com/p/healthtech-rounds-06-isomorphic-labs

  8. [getwilco.ai/clinics, retrieved 2026] AI patient follow-up by specialty | Wilco | https://www.getwilco.ai/clinics

  9. [TechCrunch, Jan 2025] Hippocratic AI raises $141M for creating patient-facing AI agents | https://techcrunch.com/2025/01/09/hippocratic-ai-raises-141m-for-creating-patient-facing-ai-agents/

  10. [Europa Press, Nov 2026] La 'startup' Wilco levanta una ronda de 2,5 millones liderada por Samaipata | https://www.europapress.es/economia/finanzas-00340/noticia-startup-wilco-levanta-ronda-25-millones-liderada-samaipata-20261119080050.html

  11. [Dealroom News, 2026] Spain's Wilco raises €2.5M for AI that keeps clinic patients from dropping off | Dealroom News | https://dealroom.co/news/174471-spain-s-wilco-raises-2-5m-for-ai-that-keeps-clinic-patients-from-droppin/

Articles about Wilco

View on Startuply.vc